Key Takeaways:
- Bariatric surgery rates fell 34% while GLP-1 prescriptions increased 140% between 2022-2024, according to major JAMA Surgery study
- Annual bariatric procedures dropped below 200,000 for first time since 2020, falling from 217,387 to 177,297 surgeries
- Despite medication surge, obesity remains undertreated with only 9.5% of eligible people receiving either GLP-1s or surgery
- Cost analysis shows GLP-1 treatment runs about $17,000 more than surgery after two years
Historic Treatment Shift Transforms Obesity Care
A seismic shift is reshaping how Americans treat severe obesity, with GLP-1 drugs increasing by 140.4 percent while bariatric surgery rates fell by 34 percent between 2022 and 2024, according to groundbreaking research published in JAMA Surgery.
The study, which analyzed data from 11.7 million patients diagnosed with obesity or diabetes, reveals the most dramatic change in obesity treatment patterns in decades. The number of metabolic and bariatric surgeries in the U.S. dropped below 200,000 in 2024 for the first time since 2020, falling from 217,387 procedures to 177,297.
"This represents a fundamental shift in how we're approaching obesity treatment," said Dr. Richard M. Peterson, president of the American Society for Metabolic and Bariatric Surgery. "GLP-1s are starting a conversation in doctors' offices that really wasn't happening as much as it should have been."
The Numbers Behind the Dramatic Shift
The research, led by Harvard T.H. Chan School of Public Health and published in 2024, tracked the accelerating trend. Between 2022 and 2023, patients undergoing surgery declined 14.4%, but this trend accelerated in 2024 with a year-on-year relative 23.0% decrease.
Meanwhile, GLP-1 adoption exploded. Between 2022 and 2023, there was a 71.8% relative increase in patients filling GLP-1s, with growth continuing between 2023 and 2024 with a 39.9% relative increase.
The shift represents more than changing preferences—it reflects improved access to effective medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) that can deliver significant weight loss without surgery.
This trend mirrors what many healthcare providers are seeing in their own practices. The convenience of taking a weekly injection versus undergoing major surgery appeals to many people, especially those who may have been hesitant about surgical options in the past.
Cost Analysis Reveals Complex Financial Trade-Offs
While GLP-1 drugs offer convenience and avoid surgical risks, the economic picture is nuanced. Recent analysis from Mayo Clinic and Baylor College of Medicine found that GLP-1 treatment costs about $17,000 more than sleeve gastrectomy ($58,600 vs. $41,400) and $7,200 more than gastric bypass ($58,600 vs. $51,300) after two years.
GLP-1 medications can cost up to $650 a month without insurance, while surgery costs between $17,000 and $26,000 and is typically covered by insurance. For people seeking more affordable options, understanding the full cost landscape and insurance coverage becomes critical.
The monthly medication costs add up quickly over time. If you're paying out of pocket for GLP-1 medications, the annual expense can reach $7,800 compared to a one-time surgical procedure that many insurance plans cover more readily.
Access Barriers Still Leave Millions Untreated
Despite the surge in GLP-1 use, the research reveals a sobering reality: obesity remains undertreated, with only about 9.5% of the relevant population undergoing treatment with GLP-1s or surgery.
Insurance coverage remains a major barrier. Insurance companies sometimes reject claims for alternative uses of GLP-1 drugs, which are expensive, even for patients who are overweight or obese. This has led many people to seek telehealth providers or compounding pharmacy alternatives for more affordable access.
The coverage landscape varies dramatically by insurance plan and state. Some people find success appealing initial denials, while others turn to telehealth options that may offer more competitive pricing for self-pay patients.
Long-Term Effectiveness Questions Emerge
While GLP-1 drugs offer impressive short-term results, questions about long-term effectiveness persist. The high cost and high rates of gastrointestinal adverse effects can lead to treatment cessation and subsequent weight regain.
Bariatric surgery, by contrast, shows durability. Studies show that most people maintain their weight loss for up to a decade after surgery, and for people with both obesity and diabetes, surgery is clearly more effective than GLP-1s for preventing deaths from cardiovascular disease.
This raises important questions about treatment sustainability. While GLP-1 medications require ongoing use to maintain benefits, surgery creates permanent anatomical changes that support long-term weight management even without ongoing medication costs.
What This Means for You
This historic shift in obesity treatment means you have more options than ever before, but choosing the right path requires careful consideration of your individual circumstances, insurance coverage, and long-term goals.
If you're considering GLP-1 treatment, start by exploring your options through our comprehensive clinic directory to find providers in your area who can assess your candidacy and insurance coverage. Many people find success with telehealth consultations, which often provide more affordable access to these medications.
For those facing insurance barriers or high costs, the landscape continues to evolve. The CMS BALANCE Model launching this year aims to expand Medicaid and Medicare coverage, potentially making these treatments more accessible.
Consider your personal situation: Are you comfortable with ongoing monthly costs and injections, or would you prefer a one-time surgical intervention? Do you have strong insurance coverage for surgery but limited coverage for medications, or vice versa? These practical considerations can guide your decision alongside medical factors.
Sources
- JAMA Surgery Study - Trends in Metabolic Bariatric Surgery Utilization in the Era of GLP-1s, 2022-2024
- The Hill - GLP-1 usage has displaced bariatric surgery for weight-loss treatment, researchers say
- Harvard T.H. Chan School - Bariatric surgeries on the decline as use of GLP-1 drugs rises
- Mayo Clinic Study - Study Finds Bariatric Surgery Less Costly Than GLP-1 Drugs Over Time
- Harvard Health - GLP-1 drugs versus bariatric surgery for treating obesity